De Novo Diagnosis of Portopulmonary Hypertension Following Liver Transplantation

Baburao Koneru, Adrian Fisher, Dorian J. Wilson, Kenneth M. Klein, Andrew N dela Torre, Joseph Seguel

American Journal of Transplantation · 2002 · 20 citations · 16 references

DOIFull text

Open access

Concepts

Abstract

Portopulmonary hypertension occurs in 2-8% of liver recipients. However, new onset of pulmonary hypertension following liver transplantation has been reported only once. We report de novo occurrences of portopulmonary hypertension in two liver recipients following successful liver transplantation. Although both patients had recurrent hepatitis C after the transplant, both had excellent clinical graft function. In one patient, upper endoscopy and aortogram showed evidence of persistent venous collaterals in the abdomen. Both patients presented with shortness of breath. Portopulmonary hypertension was diagnosed late, thus contributing directly to their deaths. Autopsy in one patient confirmed the absence of significant liver pathology and failed to demonstrate any source of deep venous thrombosis. This, and our earlier case report, highlights the potential for the occurrence of pulmonary hypertension following liver transplantation. Further studies are needed to determine the scope of the problem and identify patients at risk for this complication. Portopulmonary hypertension occurs in 2-8% of liver recipients. However, new onset of pulmonary hypertension following liver transplantation has been reported only once. We report de novo occurrences of portopulmonary hypertension in two liver recipients following successful liver transplantation. Although both patients had recurrent hepatitis C after the transplant, both had excellent clinical graft function. In one patient, upper endoscopy and aortogram showed evidence of persistent venous collaterals in the abdomen. Both patients presented with shortness of breath. Portopulmonary hypertension was diagnosed late, thus contributing directly to their deaths. Autopsy in one patient confirmed the absence of significant liver pathology and failed to demonstrate any source of deep venous thrombosis. This, and our earlier case report, highlights the potential for the occurrence of pulmonary hypertension following liver transplantation. Further studies are needed to determine the scope of the problem and identify patients at risk for this complication. Portopulmonary hypertension (PPH) is a well‐defined variant of primary pulmonary hypertension. It is associated with portal hypertension, but cirrhosis is not always present in such patients (1Lebrec D Capron J‐P Dhumeaux D Benhamou J‐P Pulmonary hypertension complicating portal hypertension..Am Rev Respir Dis. 1979; 120: 849-856PubMed Google Scholar, 2Edwards BS Weir EK Edwards WD Ludwig J Dykoski RK Edwards JE Coexistent pulmonary and portal hypertension. Morphological and clinical features.J Am C Cardiol. 1987; 10: 1233-1238Crossref PubMed Scopus (176) Google Scholar, 3Levine OR Harris RC Blanc WA Mellins RB Progressive pulmonary hypertension in children with portal hypertension.J Pediatr. 1973; 83: 964-972Abstract Full Text PDF PubMed Scopus (53) Google Scholar). Approximately 20% of patients receiving liver transplants have increased pulmonary artery pressure, and in the majority of these patients this results from changes in their circulatory physiology, which is a hallmark of portal hypertension (4Beck KC Plevak DJ Rettke SR et al.Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.Mayo Clin Proc. 1996; 10: 543-551Google Scholar). The prevalence of PPH varies from 2 to 8% in liver transplant candidates depending on the criteria used to identify such patients; when one utilizes the criteria proposed in the National Database on Pulmonary Hypertension in Chronic Liver Disease [mean pulmonary artery (PAm) pressure > 25 mmHg, pulmonary vascular resistance (PVR) > 120 dynes/s/cm−5, and pulmonary capillary wedge pressure (PCWP) < 15 mmHg] the prevalence approaches 2% (4Beck KC Plevak DJ Rettke SR et al.Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.Mayo Clin Proc. 1996; 10: 543-551Google Scholar, 5Ramsay ME Simpson BR Nguyen A‐T Ramsay KJ East C Klintmalm GB Severe pulmonary hypertension in liver transplant candidates.Liver Transplant Surg. 1997; 5: 494-500Crossref Scopus (246) Google Scholar, 6Mandell MS Krowka MJ Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease.Anesthesiology. 1997; 87: 450-451Crossref PubMed Scopus (29) Google Scholar). Portopulmonary hypertension is characterized as mild (PAm < 35), moderate (PAm 35–49) and severe (PAm ≥ 50 7Krowka MJ Plevak DJ Findlay JY Rosen CB Wiesner RH Krom RAF Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation.Liver Transpl. 2000; 6: 443-450Crossref PubMed Scopus (463) Google Scholar). While mild PPH does not increase the risk of liver transplantation, moderate and especially severe PPH are associated with markedly increased perioperative morbidity and mortality (5Ramsay ME Simpson BR Nguyen A‐T Ramsay KJ East C Klintmalm GB Severe pulmonary hypertension in liver transplant candidates.Liver Transplant Surg. 1997; 5: 494-500Crossref Scopus (246) Google Scholar, 7Krowka MJ Plevak DJ Findlay JY Rosen CB Wiesner RH Krom RAF Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation.Liver Transpl. 2000; 6: 443-450Crossref PubMed Scopus (463) Google Scholar). Successful liver transplantation has been shown to lead to resolution of PPH in some patients but not in others (8Martin M Selby R Fung J et al.Reversibility of pulmonary hypertension after liver transplantation: a case report.Transplant Proc. 1993; 25: 1789-1790PubMed Google Scholar, 9Koneru B Ahmed S Weisse AB Grant GP McKim KA Resolution of pulmonary hypertension of cirrhosis after liver transplantation.Transplantation. 1994; 58: 1133-1135Crossref PubMed Scopus (61) Google Scholar, 10Prager MC Cauldwell CA Ascher NL Roberts JP Wolfe CL Pulmonary hypertension associated with liver disease is not reversible after liver transplantation.Anesthesiology. 1992; 77: 375-378Crossref PubMed Scopus (59) Google Scholar). Because shunting of portal blood into the systemic circulation is thought to be causative in the development of PPH, it is reasonable to assume that a decrease or disappearance of the shunting may also play a role in the resolution of pulmonary vasculopathy (1Lebrec D Capron J‐P Dhumeaux D Benhamou J‐P Pulmonary hypertension complicating portal hypertension..Am Rev Respir Dis. 1979; 120: 849-856PubMed Google Scholar). On the other hand, pulmonary hypertension occurring de novo after liver transplantation has been reported only once to our knowledge (11Mandell MS Groves BM Duke J Progressive plexogenic pulmonary hypertension following liver transplantation.Transplantation. 1995; 59: 1488-1490Crossref PubMed Scopus (32) Google Scholar). Herein, we report our experience with two patients who, following successful liver transplantation, died a few years later from the consequences of pulmonary hypertension in the presence of clinically well‐functioning allografts. A 35‐year‐old Caucasian female with liver failure secondary to alcohol and hepatitis C received a liver transplant in October 1993. She was a 20 pack year smoker but had no shortness of breath or cough. Additional comorbid conditions included hypothyroidism and morbid obesity (body mass index 55.9). Chest radiogram showed a moderate‐sized right pleural effusion. Electrocardiogram showed borderline left ventricular hypertrophy. Echocardiogram showed mild enlargement of both the left atrium and ventricle but normal‐sized right chambers with mild tricuspid regurgitation. The right ventricular pressures were estimated to be normal. At transplant, her PAm was 33 mmHg (Table 1) but with normal PVR. She was discharged home 30 days after the transplant on cyclosporin and prednisone.Table 1Hemodynamic data in two patients with severe pulmonary hypertension following liver transplantationEventsPA (s/d/m)PCWCOTPRPVRPatient 1At transplant48/25/33211221878Post transplant43/24/301814.81626588 months post transplant138/55/83NA4.01660NAOn prostacyclin93/63/73NA4.51298NAPatient 221 days pretransplant32/12/22125.4326148At transplant34/16/22189.71816118 months post transplant28/14/2275.134523531 months post transplant85/38/54103.71168951NormalPAm 17 ± 312 ± 23.5 ± 0.7205 ± 5167 ± 23PA = pulmonary artery pressures (systolic/diastolic/mean), mmHg; PCW = pulmonary capillary wedge, mmHg; CO = cardiac output, L/min; TPR = total pulmonary resistance = (PAm/CO) × 80; PVR = pulmonary vascular resistance = (PAm‐PCW)/CO × 80, resistances as dynes/s/cm−5; NA = not available.The normal values are given at the foot of each column (18Barrat‐Boyce BG Wood EH Cardiac output and related measurements and pressure values in the right heart and associated vessels, together with an analysis of the hemodynamic response to the inhalation of high oxygen mixtures in healthy subjects.J Lab Clin Med. 1958; 51: 72-90PubMed Google Scholar). The Value at the foot of the CO column is for cardiac index. Open table in a new tab PA = pulmonary artery pressures (systolic/diastolic/mean), mmHg; PCW = pulmonary capillary wedge, mmHg; CO = cardiac output, L/min; TPR = total pulmonary resistance = (PAm/CO) × 80; PVR = pulmonary vascular resistance = (PAm‐PCW)/CO × 80, resistances as dynes/s/cm−5; NA = not available. The normal values are given at the foot of each column (18Barrat‐Boyce BG Wood EH Cardiac output and related measurements and pressure values in the right heart and associated vessels, together with an analysis of the hemodynamic response to the inhalation of high oxygen mixtures in healthy subjects.J Lab Clin Med. 1958; 51: 72-90PubMed Google Scholar). The Value at the foot of the CO column is for cardiac index. The patient developed hepatitis C viremia 25 months after transplantation. However, liver biopsies at this time and 45 months after the transplant showed only mild chronic portal inflammation consistent with either rejection or hepatitis. During the following year, the patient lost 110 lbs of weight through dieting and exercise and without the use any appetite suppressing medications. She presented with cough and shortness of breath 84 months after the transplant, and a chest X‐ray showed cardiomegaly, prominent pulmonary arteries and no infiltrates. A liver biopsy obtained at this time showed chronic hepatitis consistent with hepatitis C. She was treated with bronchodilators, diuretics and calcium channel blockers. As a result of a progressive increase in shortness of breath, she was hospitalized at our institution 88 months after the transplant. Echocardiogram showed a markedly dilated right ventricle and atrium with an estimated pulmonary systolic pressure of 105 mmHg. The aortic valve was sclerotic but opened normally. Left atrium was of normal size and left ventricular ejection fraction was normal. Computed tomography (CT) of the chest showed no evidence of central, lobar or segmental pulmonary artery emboli. Doppler evaluation of lower extremities, on two different occasions, showed no evidence of venous thrombosis. Arterial blood gases, while breathing room air, showed pH 7.45, pCO2 33, pO2 53, and O2 saturation 87%; administration of oxygen via a nonrebreather mask showed only minimal improvement in arterial oxygen. Laboratory tests showed total bilirubin 1.1 mg%, aspartate and alanine transferases, 27 and 12 U/L, respectively, albumin 3.5 g%, and a prothrombin normalized ratio of 1:1. At this time, she was fully awake, alert and oriented. Right heart catheterization showed severe pulmonary hypertension, which did not respond to an infusion of prostacyclin (Table 1). Despite several attempts a pulmonary capillary wedge pressure (PCWP) could not be obtained. She was not accepted for a combined heart–lung transplant because of her advanced pulmonary hypertension, and she died a few days later. Autopsy showed severe right atrial and ventricular dilatation with hypertrophy and left ventricular hypertrophy. There was no evidence of mitral stenosis, and the coronary arteries showed no obstruction. Both lungs weighed 1375 g. The major pulmonary arteries contained numerous uncomplicated atherosclerotic plaques. Muscular pulmonary arteries and arterioles showed multiple organized and recanalized thrombi with eccentric lumina (Fig. 1A). No plexiform lesions, lesions of arteritis or fibrinoid necrosis were seen. Lower extremity veins were grossly patent. The liver weighed 1700 g. All the vascular anastomoses were patent. No gross evidence of portal hypertension was noted. Microscopic examination of liver allograft showed findings typical of acute and chronic heart failure but showed no evidence of chronic hepatitis or rejection. Trichrome stain showed no evidence of fibrosis or cirrhosis (Fig. 1B). A 50‐year‐old Caucasian male with liver failure secondary to hepatitis C, resulting from treatment for factor VIII deficiency, received a liver transplant in December 1995. He was a 30 pack year smoker, had noninsulin‐dependent diabetes, systemic hypertension, and a previous episode of bacterial endocarditis. Chest radiography showed normal cardiac size and lung fields. Echocardiography showed normal‐sized chambers, small vegetation on the anterior leaflet of the mitral valve, and hypokinesis of the septum. Pulmonary pressures were estimated to be normal. Because of a positive stress test, cardiac catheterization was performed 3 weeks before the transplant and showed a PAm of 22 mmHg (Table 1). Ventriculography and coronary arteriography showed normal segmental wall motion, an ejection fraction of 74%, and 70% stenosis of the first diagonal artery. Arterial blood gases, while breathing room air, were normal. Pulmonary function tests were normal except for a diffusion capacity of 62% as predicted. Hemodynamic data obtained at the time of transplant are shown in Table 1. Sixteen months after the transplant he developed recurrence of hepatitis C, confirmed by a liver biopsy, and received a 6‐month course of alpha interferon. The patient underwent cardiac catheterization 17 months after the transplant because of recurring episodes of chest pain. Coronary angiography showed noncritical stenoses in three locations. Although the PAm was identical to the value before the transplant, the PVR was markedly increased, thus indicative of pulmonary hypertension (Table 1). Over the next several months, the patient had persistent renal insufficiency and required three medications to manage the systemic hypertension. A renal scan suggested the possibility of left renal artery stenosis, and the patient underwent aortography and renal vein rennin sampling 25 months after the transplant. This study showed no renal artery stenosis but showed numerous visceral venous collaterals. An episode of hemetemesis occurred 26 months after the transplant and gastroscopy showed congestive gastropathy. The patient's chest pains worsened and he began to develop shortness of breath on mild exertion. An echocardiogram showed left ventricular hypertrophy with decreased compliance. No valvular lesions were identified. Repeat cardiac catheterization performed 31 months after the transplant showed PAm 54, left atrial mean pressure 10 mmHg, and PVR 951 dynes.cm/s−5. Coronary arteriography showed 100% occlusion of first diagonal, 50–60% occlusion of right main coronary, and 60% and 20% stenoses of left main stem coronary. A ventilation perfusion scan indicated a low probability of pulmonary emboli. Arterial blood, while he was breathing, 2 L/min of oxygen, showed pH 7.4, pCO2 28, pO2 88 and HCO3 20. Liver function chemistries showed total bilirubin 1.0 mg%, aspartate and alanine transferases 42 and 60 U/L, respectively, alkaline phosphatase 164 U/L, gamma glutamyl transpeptidase 849 U/L, albumin 3.2 g%, and a prothrombin normalized ratio of 1:0. He was treated with continuous oxygen inhalation therapy. He died 33 months after the transplant, while being evaluated for epoprostenol therapy. Neither patient fulfilled the criteria of PPH before transplantation (6Mandell MS Krowka MJ Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease.Anesthesiology. 1997; 87: 450-451Crossref PubMed Scopus (29) Google Scholar). In the first patient, the increased cardiac output may have led to increased pulmonary pressures. Alternatively, the increased cardiac output in combination with the increased PCWP could have led to an underestimation of the PVR at the time of the transplant. The pleural effusion also may have contributed to the increased pulmonary artery pressures. In the second patient, the increased PVR seen at cardiac catheterization before the transplant could not be corroborated at the time of his transplant, probably related to the differences in cardiac outputs measured at those two time points. Following transplantation, although patient 1 had extremely high pulmonary pressures when she presented for evaluation of shortness of breath, the lack of PCWP determination limits the accuracy of the diagnosis of PPH. The evaluation carried out to exclude pulmonary thromboembolism in the second patient was limited. Although subsequent autopsy showed no evidence of a peripheral source of venous thromboemboli in the first patient, pulmonary angiography would have been a most reliable diagnostic study in identifying thromboemboli in both patients. The thrombotic vascular lesions in the lungs of our first patient raise the possibility of embolic‐type pulmonary hypertension but do not contradict the diagnosis of PPH (12Krowka MJ edWards WD A spectrum of pulmonary vascular pathology in portopulmonary hypertension.Liver Transpl. 2000; 6: 241-242Crossref PubMed Google Scholar). In a large series of patients with primary pulmonary hypertension, thrombotic lesions were present in more than 50% of the autopsy examinations, despite diligent exclusion of patients with pulmonary thromboembolism (13Fuster V Steele PM Edwards WD Gersh BJ McGoon MD Frye RL Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation. 1984; 70: 580-587Crossref PubMed Scopus (923) Google Scholar). As a result of the diffuse distribution of such thrombotic lesions, mainly in the muscular pulmonary arteries, thromboendarterectomy is not recommended in patients with primary pulmonary hypertension and would not have helped our first patient (14Rubin LJ Primary pulmonary hypertension: ACCP consensus statement.Chest. 1993; 104: 236-250Abstract Full Text Full Text PDF PubMed Scopus (349) Google Scholar). Another important feature in our report is the occurrence of severe pulmonary hypertension despite good graft function. Although both patients had chronic recurrent hepatitis C, the liver biopsies of both patients and the autopsy study of the first patient failed to demonstrate any evidence of fibrosis or cirrhosis. Portopulmonary hypertension is well documented in patients with portal vein thrombosis in the absence of cirrhosis and also following surgical portosystemic shunting (1Lebrec D Capron J‐P Dhumeaux D Benhamou J‐P Pulmonary hypertension complicating portal hypertension..Am Rev Respir Dis. 1979; 120: 849-856PubMed Google Scholar, 3Levine OR Harris RC Blanc WA Mellins RB Progressive pulmonary hypertension in children with portal hypertension.J Pediatr. 1973; 83: 964-972Abstract Full Text PDF PubMed Scopus (53) Google Scholar). The hyperdynamic circulatory changes and the enlarged portosystemic collaterals in liver recipients are known to persist for several months or even years following liver transplantation, and provide a potential opportunity for the continuation of mechanisms/factors operative before liver transplantation (15Chezmar JL Redvanly RD Nelson RC Henderson MJ Persistence of portosystemic collaterals and splenomegaly on CT after orthotopic liver transplantation.Am J Roentgenol. 1992; 159: 317-320Crossref PubMed Scopus (56) Google Scholar). While there was good evidence for the persistence of portosystemic collaterals in our second patient more than 2 years after the transplant, portal hypertension was not noted in the autopsy of our first patient. Despite the limitations, our report and the earlier report of another patient by Mandell et al. highlight the occurrence of severe pulmonary hypertension in liver recipients several months and years following liver transplantation (11Mandell MS Groves BM Duke J Progressive plexogenic pulmonary hypertension following liver transplantation.Transplantation. 1995; 59: 1488-1490Crossref PubMed Scopus (32) Google Scholar). Therefore, physicians caring for liver recipients need to consider pulmonary hypertension in the differential diagnosis of new onset of cardiopulmonary symptoms and initiate a prompt work up of such symptoms. If the evaluation reveals the presence of pulmonary hypertension, a full diagnostic work up along the established guidelines needs to be completed (14Rubin LJ Primary pulmonary hypertension: ACCP consensus statement.Chest. 1993; 104: 236-250Abstract Full Text Full Text PDF PubMed Scopus (349) Google Scholar, 16Mandell SM Evaluation of patients with portal Transplant Surg. 1997; PubMed Scopus Google Scholar). In we a liver biopsy to determine the of liver graft and an CT of the to the presence of portosystemic collaterals. If the CT persistent venous angiography and of portal vein pressure may both of our patients were diagnosed and could not be treated with any therapy. such as calcium channel and and lung or transplantation provide significant in the treatment of patients with primary pulmonary hypertension (14Rubin LJ Primary pulmonary hypertension: ACCP consensus statement.Chest. 1993; 104: 236-250Abstract Full Text Full Text PDF PubMed Scopus (349) Google and to be in the treatment of patients with PPH following liver transplantation. If the presence of a portosystemic such as a surgical or may be In patients with advanced graft liver may be needed as shown in a case report of recurrence of PPH associated with liver graft failure RC MJ portopulmonary hypertension after liver transplantation: with epoprostenol and resolution after Transpl. PubMed Scopus Google Scholar). studies identify the of patients at risk to develop PPH after liver transplantation and to such patients.

References

16